Digital Look

Welcome to Digital Look++,
you are not logged in

AstraZeneca (AZN)

Pharma and Biotech

13,632.00p

Select chart: EPS | Dividend | Revenue

Period Ending	Period	Revenue ($m)	Pre-tax ($m)	EPS	Dividend
31-Mar-26	Q1	15,288.00	3,914.00	199.00¢	n/a

Year Ending	Revenue ($m)	Pre-tax ($m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-21	37,417.00	(265.00)	8.00¢	1,445.4	n/a	-97%	287.00¢	2.5%
31-Dec-22	44,351.00	2,501.00	212.00¢	70.5	0.0	+2,550%	290.00¢	1.9%
31-Dec-23	45,811.00	6,899.00	726.00¢	19.5	0.1	+242%	290.00¢	2.1%
31-Dec-24	54,073.00	8,691.00	454.00¢	30.7	n/a	-38%	310.00¢	2.2%
31-Dec-25	58,739.00	12,402.00	660.00¢	27.8	0.6	+45%	320.00¢	1.7%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-26	62,769.11	20,239.83	761.46p	17.9	1.2	+15%	250.18p	0.0%
31-Dec-27	66,658.88	22,428.01	855.30p	15.9	1.3	+12%	261.63p	0.0%
31-Dec-28	70,666.24	24,305.88	939.65p	14.5	1.5	+10%	265.95p	0.0%

	5 Yr High	5 Yr Low	5 Yr Avg	Curr / Avg
Latest	1466.98	18.60	321.32	0.10

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

Find out about IFRS and how this affects the financial infomation for all UK companies.